Mankind Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 2609.95, up 1.9% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Mankind Pharma Ltd has slipped around 4.44% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has slipped around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 1.42 lakh shares today, compared to the daily average of 3.47 lakh shares in last one month.The PE of the stock is 51.21 based on TTM earnings ending September 24.Powered by Capital Market - Live

Mankind Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2537.6, down 3.22% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Mankind Pharma Ltd has lost around 8.04% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 2.1 lakh shares today, compared to the daily average of 3.25 lakh shares in last one month.The PE of the stock is 52.54 based on TTM earnings ending September 24.Powered by Capital Market - Live

Mankind Pharma has received reaffirmation in credit ratings from CRISIL as under: Commercial paper (Rs 5,000 crore) - CRISIL A1+ Non convertible debentures (Rs 4,600 crore) - CRISIL AA+/ Stable Non convertible debentures (Rs 400 crore) - CRISIL AA+/ Stable Total bank loan facilities rated (Rs 1,250 crore) - CRISIL AA+/ Stable Powered by Capital Market - Live

Net profit of Mankind Pharma rose 30.43% to Rs 653.47 crore in the quarter ended September 2024 as against Rs 501.03 crore during the previous quarter ended September 2023. Sales rose 13.60% to Rs 3076.51 crore in the quarter ended September 2024 as against Rs 2708.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3076.512708.10 14 OPM %27.6325.21 - PBDT954.94737.48 29 PBT849.32640.99 33 NP653.47501.03 30 Powered by Capital Market - Live

Mankind Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 2681.1, up 0.01% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 1.72% on the day, quoting at 23886.05. The Sensex is at 78452.42, down 1.6%. Mankind Pharma Ltd has gained around 4.66% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 1.9% in last one month and is currently quoting at 22807.15, down 1.17% on the day. The volume in the stock stood at 2.14 lakh shares today, compared to the daily average of 2.7 lakh shares in last one month.The PE of the stock is 57.5 based on TTM earnings ending June 24.Powered by Capital Market - Live

Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2729.95, up 3.89% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.6% on the day, quoting at 24194.3. The Sensex is at 79405.35, down 0.67%. Mankind Pharma Ltd has risen around 5.86% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has risen around 2.54% in last one month and is currently quoting at 22374.95, up 1.48% on the day. The volume in the stock stood at 1.53 lakh shares today, compared to the daily average of 2.98 lakh shares in last one month.The PE of the stock is 56.17 based on TTM earnings ending June 24.Powered by Capital Market - Live

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live

Mankind Pharma has received reaffirmation in credit rating for non-convertible debentures (Rs 4,600 crore) at ICRA AA+; Stable. The company has been assigned the rating ICRA A1+ and ICRA AA+; Stable for commercial papers (Rs 5,000 crore), non-convertible debentures (Rs 400 crore) and bank facilities (Rs 1,250 crore). Powered by Capital Market - Live

Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2631.1, up 3.76% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.3% on the day, quoting at 25867.5. The Sensex is at 84684.03, up 0.17%. Mankind Pharma Ltd has risen around 11.82% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has risen around 2.38% in last one month and is currently quoting at 23005.25, up 0.37% on the day. The volume in the stock stood at 6.1 lakh shares today, compared to the daily average of 6.37 lakh shares in last one month.The PE of the stock is 54.44 based on TTM earnings ending June 24.Powered by Capital Market - Live

The company will raise funds by way of issuance of non-convertible debentures (NCDs) and Commercial Papers (CPs) on private placement basis for an amount aggregating upto Rs 10,000 crore. The board has also constituted and authorized the Fund Raising Committee to take all necessary actions including finalization of the terms of issuance, allotment of NCDs and CPs and other related matters. Meanwhile, the company's board also approved corporate guarantees for its subsidiaries, Mankind Agritech Private, Appian Properties, Copmed Pharmaceuticals Private and Lifestar Pharma LLC. Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. The pharmaceutical company reported 10.19% increase in consolidated net profit to Rs 536.49 crore in Q1 FY25 as against Rs 486.87 crore posted in Q1 FY24.Revenue from operations stood at Rs 2,893.42 crore in Q1 FY25, up 12.20% as against with Rs 2,578.62 crore in Q1 FY24. The scrip hit all-time high at Rs 2,645 in intraday today.Powered by Capital Market - Live